{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"title":"Month 18"}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"description":"MR was defined as:\n\n* A 25-49% reduction in the level of the serum monoclonal paraprotein maintained for a minimum of 6 weeks;\n* Reduction in the 24-hour urinary light chain excretion, which still exceeded 200mg/24 hours, maintained for a minimum of 6 weeks;\n* For patients with non-secretory myeloma only, 25-49% reduction in plasma cells in a bone marrow aspirate and on a trephine biopsy, if biopsy was performed, maintained for a minimum of 6 weeks;\n* A 25-49% reduction in the size of soft tissue plasmacytomas;\n* No increase in the size or number of lityc lesions.","groups":[{"description":"Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.","id":"OG000","title":"Peginterferon α-2b"},{"description":"Participants were observed and received no treatment","id":"OG001","title":"No Treatment"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population (those who received at least one dose of study drug)","reportingStatus":"POSTED","timeFrame":"Month 9 & Month 18","title":"Number of Participants With Minimal Response (MR) to Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}